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a  b  s  t  r  a  c  t
Background:  The  presence  of bleomycin-induced  pneumomediastinum  (BIP)  in patients  with  germ  cell
tumors  (GCT)  is an uncommon  clinical  variant  within  the  spectrum  of  the lung  toxicity  associated  with
this  drug.  The  incidence  of BIP  is currently  unknown  due  to  the rarity of this  presentation.
Case description:  We  present  the  case  of  a  21-year-old  man  who  presented  with  good-risk  recurrent
disease  from  a germ  cell  tumor  two  years  after  orchiectomy  due  to disease  limited  to  the  testis.  BEP
was  planned  for 3 cycles  as a treatment  schedule.  After  administration  of  30  IU  of  bleomycin,  he  devel-
oped  pneumomediastinum  associated  with  respiratory  symptoms.  After  4  days  of  surveillance  with
conservative  management,  the patient  had  a good  response.
Conclusions:  To our  knowledge,  we present  the  first case  of BIP  after a  single  standard  dose  of  bleomycin  in
a patient  with  testicular  cancer.  Choosing  the  patient  who  would  benefit  most  from  bleomycin  to perform
individualized  treatment  could reduce  the  incidence  of toxicity  associated  with  this  drug  in patients  with
GCT. Special  attention  should  be given  to respiratory  symptoms  during  treatment  schemes  containing
bleomycin.
©  2020  The  Author(s).  Published  by Elsevier  España,  S.L.U.  This  is  an  open  access  article  under  the CC
BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).






r  e  s  u  m  e  n
Introducción:  La  presencia  de  neumomediastino  inducido  por  bleomicina  (NIB)  en  pacientes  con  tumores
de células  germinales  (TCG)  es  una  variante  clínica  poco  común  dentro  del  espectro  de  toxicidad  pulmonar
asociada  a este  fármaco.  La  incidencia  de NIB es  actualmente  desconocida  debido  a su  rareza.
Caso  clínico:  Presentamos  el  caso  de  un  hombre  de  21  años  de  edad  que  se  presentó  con  recurrencia  de
un  tumor  germinal  mixto  posterior  a dos  años  de  vigilancia  tras  orquiectomía  por  enfermedad  limitada
al  testículo.  Se  planteó  como  esquema  de  tratamiento  el  régimen  BEP.  Tras la primera  administración
de  30  UI  de  bleomicina  desarrolló  neumomediastino  aislado.  Posterior  a 4 días  de  vigilancia  con  manejo
conservador  presentó  buena  respuesta.
Conclusiones:  Presentamos  el primer  caso  de  NIB  tras  una  sola  dosis  de  bleomicina  en  un paciente
con  cáncer  testicular.  Elegir  al  paciente  que se  pudiera  beneficiar  más  con  el uso  de  bleomicina,  indi-
vidualizando  su utilización,  pu
pacientes  con  TCG.  Se  debe  pre
con  esquemas  que  contengan  
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Bleomycin is an antitumoral drug that belongs to the family of
lycopeptide antibiotics isolated from the strain Streptomyces ver-
icillus which is used in patients with a diagnosis of non-Hodkin
ymphoma and in individuals who suffer germinal tumors and some
quamous carcinomas. Its therapeutic effect is limited due to its
otential for lung toxicity, which is known as bleomycin-induced
ung injury (BILI), a condition that has a mortality of 1–3%.1
The presence of bleomycin-induced pneumomediastinum (BIP)
n patients with germ cell tumors (GCT) is an uncommon clini-
al variant within the spectrum of lung toxicity associated with
his drug. The incidence of BIP is unknown due to the rarity of
his presentation, especially in the context of isolated pneumome-
iastinum. Despite the lack of information regarding this clinical
ntity, the presence of BIP could be associated with a poorer prog-
osis and a worse therapeutic outcome in these patients.2
We  present the case of a young man  with isolated pneumome-
iastinum associated with a single standard dose of bleomycin.
linical case
A 21-year-old man  came to the emergency department of our
ospital complaining of a four-day history of abdominal pain radi-
ting to the right flank. He was diagnosed with a clinical-stage IB
ight testicular mixed germ cell tumor treated two years before
ith radical orchiectomy and subsequent surveillance. Imaging
tudies revealed recurrent metastatic disease to the left inguinal
ymph nodes, the mediastinum and the retroperitoneum; the latter
ausing compression of the right ureter, the inferior vena cava, and
hrombosis of the right common iliac vein to the common femoral
ein. Unmeasurable disease was documented in relation to bilat-
ral lung involvement. Renal, liver and bone marrow function tests
ere normal; AFP was 17.28 ng/mL (normal range 0–10 ng/mL),
nd B-HCG 1.15 mIU/mL (normal values 0–5 mIU/mL). The case
as initially evaluated by a multidisciplinary team and systemic
reatment based on bleomycin, etoposide, and cisplatin (BEP) was
ffered for three cycles due to good risk features. The first cycle
as planned for in-hospital administration. The calculated doses
ere bleomycin 30 IU on days 1, 8, and 15; etoposide 100 mg/m2,
nd cisplatin 20 mg/m2 on days 1–5. After the application of the
ig. 1. (a) Posteroanterior chest X-ray that shows the presence of air in soft tissues of the
n  peri-tracheal and left axillary soft tissues (arrows).Fig. 2. Posteroanterior chest X-ray after 72 h of conservative management with the
disappearance of soft tissue air.
first 30 IU of bleomycin, the patient presented sudden pleuritic
chest pain located in the left hemithorax and associated with dysp-
nea at rest. On physical examination, subcutaneous emphysema
was detected in the ipsilateral neck and supraclavicular region.
Imaging studies revealed pneumomediastinum and subcutaneous
emphysema without pneumothorax (Fig. 1). Conservative man-
agement was  provided with supplemental oxygen; clinical and
radiographic resolution occurred after 4 days of observation (Fig. 2).
After monitoring with a favorable evolution, hospital discharge
was authorized. In the patient’s first outpatient assessment, it was
decided to suspend bleomycin and change the treatment scheme
to etoposide and cisplatin (EP) at standard doses.Discussion
The clinical presentation of BIP is variable and includes a wide
spectrum of thoracic symptoms such as dyspnea, cough, chest pain,




































orax complicating chemotherapy for metastatic seminoma. A case report and a
review of the literature. Cancer 1995;75:2710–3.R.J. Martínez-Granados et al. 
ales, opacities on imaging studies, such as chest X-ray or CT scan,
nd decreased lung capacity detected by studies, such as the dif-
using capacity of the lungs for carbon monoxide (DLCO). BIP can
ccur as early as the first month of treatment or as a late pulmonary
oxicity 10 years after the end of bleomycin treatment as described
y Tashiro et al.3 Lung toxicity from bleomycin has been related
o the activity of the enzyme bleomycin-hydroxylase which deac-
ivates this drug. Genetic variability in its activity has been found
n some studies,4 leading to greater susceptibility in patients who
ave a lower function of this enzyme for the development of an
nflammatory mechanism mediated by cytokines and free radicals
f endothelial damage of the lung vasculature with the subsequent
linical picture manifested as BILI.5 Renal failure, a body mass index
BMI) less than 22 kg/m2, the use of granulocyte colony-stimulating
actor, tobacco use, the presence of prior interstitial lung pathology,
 cumulative dose greater than 300 IU of bleomycin, previous irra-
iation or involvement of the lung parenchyma due to metastatic
esions have been described in the literature as risk factors for the
evelopment of BILI.6–9
Most of the literature and the current medical review of this
linical presentation concludes as a major precipitant a greater
mount of accumulated dose of bleomycin, mostly with the late
evelopment of concomitant interstitial pneumopathy10 together
ith multiple pulmonary metastatic lesions with high chemosen-
itivity as occurs in testicular germ cell tumors9; however, the
elevance of this clinical case is the atypical presentation where
neumomediastinum developed after the first dose of 30 IU.
To our knowledge, we present the first case of BIP after one
tandard dose of bleomycin. We  encourage future trials with sta-
istical power to predict which patients will benefit the most from
leomycin and therefore reduce the incidence of toxicity in those
ho will not have a significant benefit from this drug. The physician
ust consider the probability of BILI within the initial approach
f a patient with any pulmonary symptom during treatment with
leomycin; this will facilitate timely diagnosis in order to avoid
ife-threatening complications.
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